Introduction
The annual spend on emollients in England alone in 2015/16 was £116.2 million. 1 Despite their accepted value in dry skin conditions such as atopic eczema, there are multiple products which come in different formulations (ointments, gels, creams, lotions, sprays and bath additives) and a weak evidence base to guide their use. [2] [3] [4] Most prescribing of emollients happens in primary care and Clinical Commissioning Groups (CCGs) in England and Local Health Boards (LHBs) in Wales, who have the responsibility for the provision of NHS care on their locality, maintain local prescribing formularies. NICE guidelines states that such information should be published "… in a clear, simple and transparent way, so that patients, the public and stakeholders can easily understand it." 5 The need for multiple formularies is questionable, although the number, type and content of recommendations made has never been examined. Therefore, we sought to identify and compare the structure and content of emollient formularies across England and Wales, including any rationale behind the recommendations given.
Methods

Data collection
First, CCGs in England and LHBs in Wales were identified using the NHS choices (www.nhs.uk) & NHS England websites (www.england.nhs.uk, as listed in October 2016) and the NHS Wales website (www.wales.nhs.uk, February 2017). All available formularies were identified by systematically searching each CCG/LHB website or undertaking Google searches using relevant keywords.
JPC and GB extracted data from each formulary into "leave on" and bath additive Excel® spreadsheets templates respectively. These templates were initially piloted and developed with a sample of formularies. To ensure consistency of data extraction, a codebook detailing the various coding options was developed alongside. An independent check of 10 formularies identified discrepancies in 4.7% (57/1220) of "leave on" emollient (PAQ) and 9.8% (44/448) of bath additive (JPC) data points.
Analysis
Data were then imported and analysed descriptively using STATA (v14). All percentages were rounded to the nearest whole number unless stated otherwise.
Patient involvement
"Which emollient is the most effective and safe in treating eczema" was identified as a priority for research in a patient and clinician-led prioritisation exercise published in 2013.6 Public and patient involvement in subsequent eczema research led by MJR has reinforced the importance of understanding the variation in emollient prescribing and recommendations made by different doctors and specialist nurses better. [7] [8] [9] However, patients were not involved in the design of the study or the interpretation of the findings. Patients were not involved in design, conduct or analysis during this study.
Results
89% (185/209) of CCGs had an emollient formulary and all seven LHBs had an emollient formulary ( Fig. 1 ). 71% (131/185) CCGs shared an emollient formulary with at least one other CCG, but all 7 LHBs had their own individual emollient formulary. Some CCGs (24/209) withheld formularies for internal use only or did not respond, even after direct correspondence, meaning data could only be collected from 89% of CCGs. Therefore, overall 102 formularies were examined.
The structure of formularies varied but for emollients most (63%, 64/102) adopted a "rank" (traffic light, medal or number) structure, with by formulation (51%, 52/102) being next most common, followed by basic (alphabetical) list (47%, 48/102) and by skin dryness (10%, 10/102) (categories not mutually exclusive). 34% (35/102) of formularies gave the specific costs for each emollient.
Emollients
Over 109 different emollients were named, with 93 of these recommended by at least one formulary. Almost every formulary recommended at least one cream (99%) or ointment (98%) (see Table 1 ). Most formularies also recommended at least one lotion or gel (both 85%), but only 29% recommending a spray. No formularies actively recommended against use of creams, lotions, ointments or gels. However, 9% of formularies did not recommend sprays and most formularies (62%) made no mention of them. 'Other' emollients were most commonly (58%) not recommend by formularies. This category contained more unusual products such as food based oils and balms (Table S1 ).
Cream and ointments were the most commonly recommended types of emollients (table 2) , with 99% and 98% of formularies recommending at least one product from each group respectively. Of specifically recommended emollients, three of the "top five" are ointments (Table 2) . However, between 2% and 9% of formularies specifically did not recommend one or more of these products. When ranked by emollient type (lotion, cream, gel and ointment), three products which contain urea or antimicrobials (Dermol 500 Lotion, Dermol Cream, Balneum plus Cream) appear in the "top five" (table S2) . Among the 64 formularies that specified an order of preference for recommended emollients, generic emulsifying ointment was the most popular first-line emollient, followed by three "Zero" products and white soft/liquid paraffin 50/50 (table S3) . Aqueous cream was the most commonly not recommended emollient (45% of formularies, Table 2 ), although again there was disagreement between formularies, with up to 16% recommending one or more of the top five emollients not recommended.
The most common reasons given for the recommendations made were patient preference (60%, 61/102) and/or product cost (58%, 59/102). 42% (43/102) of formularies gave other reasons, the most common being "the greasier the emollient, the better the effect". Other rationale given for not recommending emollients included concerns over food based ingredients and the ability of active ingredients to penetrate the skin. No rationale was given in 28% (29/102). 
Bath additives
Of the 82% (84/102) of formularies that recommended the use of bath additives, 75% (64/84) did not give any rationale. Six formularies noted that evidence to support their use was lacking, eight recommended their use only in specific circumstances and six cited "possible benefit for some patients".
There was no mention of bath additives in 7% (7/102) of formularies and 11% (11/102) did not recommend their routine use. 4% (4/102) stated that patients should buy their own. The rational to justify not prescribing bath emollients was variable, the most common (non-exclusive) reasons cited were: lack of evidence (5/11), concerns about safety (4/11), the potential to under-treat eczema by distracting from leave-on emollient use (3/11) and cost (1/11). Three formularies did not give a reason.
Most formularies (92%, 77/84) presented their recommendations as individually named bath additives. A small number of formularies (8%, 7/84) also suggested that any emollient (except for "50:50") could be used in the bath instead of a specific bath additive. Regarding the use of bath additives with antimicrobials, they were recommended in 74% (62/84) of formularies, not mentioned in 25% (21/84), and one advised against their use ever. Of those recommending their use, 34% (21/62) specified only "in the presence of infection".
Overall 19 regular and five antimicrobial containing bath additives were named (see table 3 ). No bath emollients were specifically listed as not recommended. The five most commonly recommended bath emollients were Oilatum, Hydromol, Dermol 600, Oilatum plus and Balneum plus. Some formularies restricted use of specific bath additives, for example Aveeno was often only recommended if paraffin intolerant or following no response to other bath emollients.
Discussion
We found that most CCGs and LHBs (192/216) had a formulary, with 102 unique emollient formularies between them. Of the 109 different emollients named, creams and ointments were the most commonly recommended types and three ointments (White soft/Liquid paraffin 50/50, Emulsifying ointment and Hydromol ointment) the most frequently specified products. However, there was poor consensus over which emollient should be used first-line and four out of ten of the most recommended lotions and cream contained antimicrobials or urea. Patient preference (60%) and/or cost (58%) were the most commonly reasons given for the recommendations. However, cost recommendations were on a "price per gram or millilitre" basis, rather than proper costeffectiveness evidence. 11% of formularies did not recommend their use of bath additives, while the 82% that did named 24 different bath additives and most (75%) did not give any reasons for their recommendation.
This is the first study to compare all emollient formularies in England and Wales. Formularies were identified, and data extracted, in a systematic way. Ambiguity in many of the formularies, differences in interpretation and transcription errors may mean inaccuracies were introduced during this process. In the time between collecting and reporting the data, two further CCGs have merged (new total 207) and a rapid review of the emollient formularies in November 2017 identified that 50% have been updated. However, most changes appear to be minor and the key findings of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y number of formularies and similarities/differences between the different formularies hold true. Because of the labour-intensive nature of data extraction, the constant change in NHS service configuration, and CCGs/LHBs independently maintaining >100 formularies, it is impossible to have an up-to-date national picture at any one point in time. Very few formularies referred to specific diseases or populations (age, ethnicity), so we were unable report recommendations at this level.
One significant factor contributing to the lack of agreement between the formularies is the weak evidence base. Several recent systematic reviews have all concluded that good quality research comparing the effectiveness or acceptability of emollients is very limited. [2] [3] [4] Likewise, there is an
absence of evidence to demonstrate the clinical and cost effectiveness of bath additives. 3 The greatest consensus is around recommendations for ointments, one appeal being their low cost, although current NICE guidance on atopic eczema in children (from 2007) notes that they are often less acceptable and are therefore "not usually suitable as a first-line treatment". 10 The predominance of emollients which contain urea or antimicrobials is surprising: these products are usually second-line treatments, generally cost more than standard emollients, and are more likely to irritate skin. It is encouraging to see 45% of formularies actively not recommending aqueous cream, probably reflecting the 2013 MHRA safety report on adverse skin reactions in children with eczema. 11 There is a disparity between formulary recommendations and recent community dispensing data from NHS England 12 13 where the top five dispensed emollients were Cetraben cream, Doublebase gel, Diprobase cream, Aveeno cream and Dermol 500 lotion. This may be due to a lag between formulary implementation and prescribing patterns changing, wilful ignorance of formularies on the part of prescribers or strong patient preference for alternative emollients.
We know that much emollient prescribing is done on a "trial and error" basis, 14 15 and it is unclear the extent to which all these different formularies help reduce (or indeed contribute) to this problem. While local formularies can reflect the needs of needs of the population served, the justification in the case of emollients/bath additives is weak (and indeed local factors contributing to decision making not specified in any of the formularies). Furthermore, we cannot understand why the formularies of 24 CCGs are not publicly available. In addition to the time and cost of different medicine management teams and area prescribing committees developing individual emollient formularies, differences between them serves to cause confusion to prescribers and patients, especially when they move between areas. This combined with the discrepancy between emollient dispensing data and formulary recommendations suggests the purpose of emollient formularies should be rethought and/or communicated more effectively.
While the "correct" emollient is the "one that the child will use", 10 is a pragmatic approach to emollients prescribing, it is not one that is supported by formulary recommendations that have a weak evidence base. Future research should further explore the disparity between recommended and observed prescribing of emollients, including changes over time in formulary recommendations and prescribing patterns. The results of on-going pragmatic trials such as Best Emollient for Eczema (BEE, comparing different emollient types) and Bath Additives for the Treatment of Childhood Eczema (BATHE, bath additives in addition to usual care) will provide clinical and cost-effectiveness data which will inform, and hopefully unify, formulary recommendations to the benefit of patients and clinicians. 
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Wales vary widely in their structure, recommendations and rationale. The reasons for such inconsistencies are unclear, risk confusion and make for inequitable regional variation. There is poor justification for multiple different, conflicting formularies.
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Strengths and limitations of this study
• This is the first study to compare in a systematic way all of the emollient formularies in England and Wales.
• Due to the labour-intensive nature of data extraction and constant change in CCG/LHB service configuration and formularies, it is impossible to have an up-to-date national picture at any one point in time.
• Very few formularies referred to specific diseases or populations (age, ethnicity), so we were unable report recommendations at this level.
• Ambiguity in many of the formularies, differences in researcher interpretation, and transcription errors may mean inaccuracies were introduced during the data extraction process. The need for multiple formularies is questionable, although the number, type and content of recommendations made has never been examined. Therefore, we sought to identify and compare the structure and content of emollient formularies across England and Wales, including any rationale behind the recommendations given.
Methods
Data collection
First, CCGs in England and LHBs in Wales were identified using the NHS choices (www.nhs.uk), NHS England (www.england.nhs.uk, as listed in October 2016) and NHS Wales websites (www.wales.nhs.uk, February 2017). All available formularies were identified by systematically searching each CCG/LHB website or undertaking Google searches using relevant keywords.
JPC and GB extracted data from each formulary into "leave on" and bath additive Excel® spreadsheets templates respectively. These templates were initially piloted and developed with a sample of formularies. To ensure consistency of data extraction, a codebook detailing the various coding options was developed alongside. An independent check of 10 formularies identified discrepancies in 4.7% (57/1220) of "leave on" emollient (PAQ) and 9.8% (44/448) of bath additive (JPC) data points. Where disagreements arose, the two data extractors discussed and agreed what should be recorded; most stemmed from differing interpretations of vague and/or inconsistent formularies, rather than random errors.
Analysis
Patient involvement
"Which emollient is the most effective and safe in treating eczema?" was identified as a priority for research in a patient and clinician-led prioritisation exercise published in 2013. 6 Public and patient involvement in subsequent eczema research led by MJR has reinforced the importance of understanding the variation in emollient prescribing and recommendations made by different 
Results
89% (185/209) of CCGs had an emollient formulary and all seven LHBs had an emollient formulary (Fig. 1) . 71% (131/185) CCGs shared an emollient formulary with at least one other CCG, but all 7 LHBs had their own individual emollient formulary. Some CCGs (24/209) withheld formularies for internal use only or did not respond, even after direct correspondence, meaning data could only be collected from 89% of CCGs. Therefore, overall 102 formularies were examined.
Emollients
Over 109 different emollients were named, with 93 of these recommended by at least one formulary. Almost every formulary recommended at least one cream (99%) or ointment (98%) (see Table 1 ). Most formularies also recommended at least one lotion or gel (both 85%), but only 29% recommended a spray. No formularies censuredthe use of creams, lotions, ointments or gels. However, 9% of formularies recommended against sprays and most formularies (62%) made no mention of them. 'Other' types of emollients were most commonly (58%) not recommend by formularies. This category contained more unusual products such as food-based oils and balms (Table S1 ).
Cream and ointments were the most commonly recommended types of emollients (Table 2) , with 99% and 98% of formularies recommending at least one product from each group respectively. Of specifically recommended and named emollients, three of the "top five" are ointments (Table 2) . However, between 2% and 9% of formularies specifically did not recommend one or more of these products. When ranked by emollient type (lotion, cream, gel and ointment), three products which contain urea or antimicrobials (Dermol 500 Lotion, Dermol Cream, Balneum plus Cream) appear in the "top five" (table S2) . Among the 64 formularies that specified an order of preference for recommended emollients, generic emulsifying ointment was the most popular first-line emollient, followed by three "Zero" products and white soft/liquid paraffin 50/50 (Table S3) . Aqueous cream was the most common emollient not recommended (45% of formularies, Table 2 ), although again there was disagreement between formularies, with up to 16% recommending one or more of the top five not recommended emollients.
The most common reasons given for the recommendations made were patient preference (60%, 61/102) and/or product cost (58%, 59/102). 42% (43/102) of formularies gave other reasons, the most common being "the greasier the emollient, the better the effect". Other rationale given for not recommending emollients included concerns over food-based ingredients and the ability of active ingredients to penetrate the skin. No rationale was given in 28% (29/102). 
Bath additives
There was no mention of bath additives in 7% (7/102) of formularies and 11% (11/102) did not recommend their routine use. 4% (4/102) stated that patients should buy their own. The rational for not prescribing bath emollients was variable, the most common (non-exclusive) reasons cited were: lack of evidence (5/11), concerns about safety (4/11), the potential to under-treat eczema by distracting from leave-on emollient use (3/11) and cost (1/11). Three formularies did not give a reason.
Most formularies (92%, 77/84) presented their recommendations as individually named bath additives. A small number of formularies (8%, 7/84) also suggested that any emollient (except for "50:50") could be used in the bath instead of a specific bath additive. Regarding the use of bath additives with antimicrobials, they were recommended in 74% (62/84) of formularies, not mentioned in 25% (21/84), and one advised against their use ever. Of those recommending their use, 34% (21/62) specified "only in the presence of infection".
Overall 19 regular and five antimicrobial containing bath additives were named (see table 3 ). The five most commonly recommended bath emollients were Oilatum, Hydromol, Dermol 600, Oilatum plus and Balneum plus. Some formularies restricted use of specific bath additives, for example Aveeno was often only recommended if paraffin intolerant or following no response to other bath emollients.
Discussion
We found that most CCGs and LHBs (192/216) had a formulary, with 102 unique emollient formularies between them. Of the 109 different emollients named, creams and ointments were the most commonly recommended types and three ointments (White soft/Liquid paraffin 50/50, Emulsifying ointment and Hydromol ointment) the most frequently specified products. However, there was poor consensus over which emollient should be used first-line and four out of ten of the most recommended lotions and cream contain antimicrobials or urea. Patient preference (60%) and/or cost (58%) were the most common reasons given for the recommendations. However, cost recommendations were on a "price per gram or millilitre" basis, rather than proper costeffectiveness evidence. 11% of formularies did not recommend their use of bath additives, while the 82% that did named 24 different bath additives and most (75%) did not give any reasons for their recommendation.
This is the first study to compare all emollient formularies in England and Wales. Formularies were identified, and data extracted, in a systematic way. Ambiguity in many of the formularies, differences in interpretation and transcription errors may mean inaccuracies were introduced during this process. In the time between collecting and reporting the data, two further CCGs have merged (new total 207) and a rapid review of the emollient formularies in November 2017 identified that 50% have been updated. However, most changes appear to be minor and the key findings of the
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number of formularies and similarities/differences between the different formularies hold true. Because of the labour-intensive nature of data extraction, the constant change in NHS service configuration, and CCGs/LHBs independently maintaining >100 formularies, it is impossible to have an up-to-date national picture at any one point in time. Very few formularies referred to specific diseases or populations (age, ethnicity), so we were unable report recommendations at this level.
absence of evidence to demonstrate the clinical and cost effectiveness of bath additives. 3 The greatest consensus is around recommendations for ointments, one appeal being their low cost, although current NICE guidance on atopic eczema in children (from 2007) notes that they are often less acceptable and are therefore "not usually suitable as a first-line treatment". 10 The predominance of emollients which contain urea or antimicrobials is surprising: these products are usually second-line treatments, generally cost more than standard emollients, and are more likely to irritate skin. 1 11 It is encouraging to see 45% of formularies actively not recommending aqueous cream, probably reflecting the 2013 MHRA safety report on adverse skin reactions in children with eczema. 12 There is a disparity between formulary recommendations and recent NHS community dispensing data (for children and adults) 13 14 where the top five dispensed emollients were Cetraben cream, Doublebase gel, Diprobase cream, Aveeno cream and Dermol 500 lotion. There may be many reasons for this observation, beyond the scope of this paper, but which may include: a time lag between formulary implementation and prescribing patterns changing; prescriber lack of familiarity with formulary recommendations; and/or strong clinician or patient preference for nonrecommended emollients.
We know that much emollient prescribing is done on a "trial and error" basis, 15 16 but it is unclear the extent to which all these different formularies help reduce (or indeed contribute) to this problem. While local formularies can reflect the needs of the population served, the justification in the case of emollients/bath additives is weak (and indeed local factors contributing to decision making not specified in any of the formularies). Furthermore, we cannot understand why the formularies of 24 CCGs are not publicly available. In addition to the time and cost of different medicine management teams and area prescribing committees developing individual emollient formularies, differences between them serves to cause confusion to prescribers and patients, especially when they move between areas. This combined with the discrepancy between emollient dispensing data and formulary recommendations suggests the purpose of emollient formularies should be rethought and/or communicated more effectively.
While the "correct" emollient is the "one that the child will use", 10 is a pragmatic approach to emollient prescribing, it is not one that is supported by formulary recommendations that have a weak evidence base. Future research should further explore the disparity between recommended and observed prescribing of emollients, including changes over time in formulary recommendations and prescribing patterns. The results of on-going pragmatic trials such as Best Emollient for Eczema (BEE, comparing different emollient types) and Bath Additives for the Treatment of Childhood Eczema (BATHE, bath additives in addition to usual care) 17 will provide clinical and cost-effectiveness data which will inform, and hopefully simplify, formulary recommendations to the benefit of patients and clinicians. 
Conflicts of interests
Dr Ridd reports grants from National Institute for Health Research (NIHR) Post Doctoral Fellowship (PDF-2014-07-013) and NIHR HTA (11/153/01 and 15/130/07). Mr Chan and Ms Boyd report grants from The Academy of Medical Sciences INSPIRE scheme. Mr Quinn has nothing to disclose. Funders of this study had no role in the study design; collection, analysis, and interpretation of the data; writing of the manuscript; or decision to submit the manuscript for publication. The authors are independent from funders.
Ethics
This study did not require ethics approval. 
Transparency
The lead author (JPC) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 5 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 o n l y 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 
